Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.
about
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaSeven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseEnhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Immune Modulation in Hematologic MalignanciesRecent clinical studies of the immunomodulatory drug (IMiD) lenalidomideLenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsLack of in vitro antimicrosporidian activity of thalidomideAn erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndromeThe next generation of novel therapies for the management of relapsed multiple myeloma.Emerging drugs for chronic lymphocytic leukaemia.Selective leukemic-cell killing by a novel functional class of thalidomide analogsAlternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Thalidomide for the treatment of idiopathic myelofibrosis.Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).Immunomodulation by thalidomide and thalidomide analoguesAngiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Thalidomide: a remarkable comeback.Update on therapy--thalidomide in the treatment of lupus.The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.Immunotherapeutic and antitumour potential of thalidomide analogues.Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Small therapeutic molecules for the treatment of inflammatory bowel diseaseSafety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Thalidomide as an anti-cancer agent.Thalidomide: an old drug with new clinical applications.Novel therapeutic approaches for pulmonary fibrosis.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Thalidomide for erythema nodosum leprosum and other applications.Thalidomide: a new anticancer drug?Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.
P2860
Q24605861-5AC8A102-77B2-4143-AD64-01ACE4FD6372Q24651269-F4AA16DF-B0C2-44B2-90C0-32110D581F99Q24685895-82878327-3C9E-45C7-B11E-90DA8B49C7DEQ26770391-192C486B-E2BF-4829-8678-6B0574365D05Q26796307-F5566E88-74E5-47AA-82F5-A73A2BF7F6EAQ28192646-93FF9C42-DCC9-4A9B-90DE-509AC0716D63Q28303091-C51A0D39-4D04-456B-8000-E5D712975094Q28343553-C643ED52-098B-4ABE-A266-171B5520C6FBQ28472171-E8D7E7C0-A448-48FF-AF08-358B81216551Q30248534-E213474E-16DF-44F4-8648-BCE2B835A878Q30353154-6D0A0B9E-836B-4237-A805-1439409CCBA2Q30479632-6942C381-19E3-4827-AE21-213EDCFB5227Q33322921-2498DF0F-5CAA-4994-A3CE-1777C27E03F8Q33359542-7680F1FD-E81B-447B-9BD2-ED95BE5D4F43Q33360969-6BC30A88-FCC8-4967-8EDD-A3147F75C8D8Q33364235-1009C697-9D7D-404D-916B-58785CC212E3Q33391803-BDD121FB-7B85-4AEE-8FA6-7DA05D442BE9Q33436535-6BCE7368-FB0C-44B3-8E59-7F76E3D335CBQ33611998-5EE2A4C5-4A4C-46A8-8952-229C07D25E01Q33655628-29F2150F-FD6C-451B-BB3B-36FB7E4F70E2Q33782386-4A7F253F-ABF6-46F9-89BF-E20F8779C599Q34109028-91BDF3CA-5C57-47F3-BD26-AFA630A55E45Q34109469-11ADB468-4362-4204-A2A2-615C4C2FE9CFQ34165935-366E7B40-FB56-4940-8C44-2E97FF483FA3Q34182143-602D4184-6591-47C4-A4C9-342CBA76D482Q34227018-819DF699-2A29-485C-923C-DBD650474945Q34289226-F6C04694-E3D9-4645-95CA-B70DC152A40BQ34451909-8D685C8B-7833-4958-8163-C21E86925BC4Q34454532-6D3D7940-02B8-4528-A465-21E282014392Q34600992-159F685A-D1C5-4610-9629-3E728617FBEFQ34666858-74D5FECA-56F1-4BAA-8E17-C596E299EDB6Q34775475-DC5912BC-4908-4A60-9CB3-6920B1DD4796Q34778074-14EB92FC-09CB-43D5-8311-58A5DE76F69FQ34798767-C53D402E-BBED-4034-8B88-4C6877EEFF5AQ34903224-C13CF7AE-5C47-4249-A502-913F99095AE0Q35026302-AA8B5B23-6DE9-4768-AFB3-FA46D34FD90AQ35101473-4083B75C-4B5F-49CA-B71D-A954E399EE4FQ35164773-8819A67B-6FDA-4607-9317-B790B96B6280Q35171777-BE2DDC2C-A845-469A-BD78-36260A9F04CEQ35175287-26A4C626-6006-4E80-A1BE-1BD83120D41A
P2860
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@en
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@nl
type
label
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@en
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@nl
prefLabel
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@en
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@nl
P2093
P2860
P356
P1476
Thalidomide costimulates prima ...... responses in the CD8+ subset.
@en
P2093
P2860
P304
P356
10.1084/JEM.187.11.1885
P407
P577
1998-06-01T00:00:00Z